Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Ventana MMR RxDx Panel has received FDA approval for advanced or recurrent endometrial cancer patients. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login